TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)

K. I. Zarubina; Зарубина К. И.; E. N. Parovichnikova; Паровичникова Е. Н.; O. A. Gavrilina; Гаврилина О. А.; A. N. Sokolov; Соколов А. Н.; V. V. Troitskaya; Троицкая В. В.; L. A. Kuzmina; Кузьмина Л. А.; V. E. Mamonov; Мамонов В. Е.; G. M. Galstyan; Галстян Г. М.; V. G. Savchenko; Савченко В. Г.

doi:10.17650/1818-8346-2017-12-3-41-49

TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)

Authors: Zarubina K.I.¹, Parovichnikova E.N.¹, Gavrilina O.A.¹, Sokolov A.N.¹, Troitskaya V.V.¹, Kuzmina L.A.¹, Mamonov V.E.¹, Galstyan G.M.¹, Savchenko V.G.¹
Affiliations:
1. National Research Center for Hematology, Ministry of Health of Russia
Issue: Vol 12, No 3 (2017)
Pages: 41-49
Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
Published: 25.10.2017
URL: https://oncohematology.abvpress.ru/ongm/article/view/257
DOI: https://doi.org/10.17650/1818-8346-2017-12-3-41-49
ID: 257

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cytotoxic drugs, enhancing myelotoxicity and, as a consequence, infections and thrombo-hemorrhagic complications. In addition, complex inter-drug interactions lead to the manifestations of combined toxicity. This article presents a case report of patient with relapsed acute Ph-positive lymphoblastic leukemia, treatment of which was accompanied by numerous complications, especially during treatment of II and III generation tyrosine kinases inhibitors.

Keywords

Ph-positive acute lymphoblastic leukemia, tyrosine kinase inhibitors, selectivity, combined toxicity, T315I mutation, imatinib, nilotinib, dasatinib, axitinib, ponatinib, blinatumomab